Lantern Pharma Initiates Human Trials with AI-Driven Drug Candidate LP-284

Lantern Pharma, a company listed on NASDAQ (LTRN), is pioneering the use of artificial intelligence (AI) to develop innovative cancer treatments. Their AI-driven drug candidate, LP-284, has entered a Phase 1 clinical trial, marking a significant step in the fight against cancer. This compound is being tested as a possible treatment for patients with non-Hodgkin’s lymphoma and other solid tumors that have relapsed or are refractory to current treatments.

LP-284 represents the second molecule in Lantern's portfolio that targets synthetic lethality in cancers with deficiencies in DNA repair mechanisms. The drug candidate has been brought to clinical trials through the application of AI, machine learning, and computational biology, making it the third such compound to reach this stage by the company.

The company's President and CEO, Panna Sharma, highlighted the importance of this milestone, stating that LP-284 holds the potential to significantly improve the prognosis for an estimated 40,000 to 80,000 patients suffering from blood cancers each year. The global market potential for LP-284 is estimated to be around $4 billion annually.

Lantern's AI platform, RADR®, has been instrumental in the development of LP-284, with the system expected to process over 100 billion data points in 2024. RADR® has facilitated the identification and prioritization of cancer indications for LP-284 and other drug candidates in development.

The Phase 1 clinical trial (NCT06132503) is an open-label, multicenter study designed to assess the safety, tolerability, and pharmacokinetics of LP-284, as well as to establish the maximum tolerated dose and the recommended Phase 2 dose. The trial will involve up to 30 patients in the dose escalation phase and may expand to include up to 40 patients in each of two specific tumor cohorts in a subsequent phase.

Lantern Pharma's approach to drug development is distinguished by its efficiency and cost-effectiveness. The company has been able to progress LP-284 from concept to human trials in under three years and at a cost of less than $3 million, demonstrating the transformative impact of AI on drug discovery.

The company's pipeline includes a Phase 2 program and several Phase 1 trials, and they have established a subsidiary, Starlight Therapeutics, focused on CNS and brain cancer therapies. Lantern Pharma's pipeline is estimated to have a combined annual market potential exceeding $15 billion, with the potential to deliver transformative treatments to hundreds of thousands of cancer patients globally.

Lantern Pharma's mission is to revolutionize oncology drug development by leveraging AI and machine learning to solve complex challenges in the field. Their RADR® platform, which utilizes a vast database of oncology-focused data and advanced algorithms, is a testament to their commitment to this goal. The company's forward-thinking approach aims to streamline the drug development process, reduce risks, and expand the possibilities for cancer treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!